Please login to the form below

Not currently logged in

Testing for new Alzheimer's treatment

American pharma company Eli Lilly & Co announced on March 31 the start of a phase III clinical trial for a new Alzheimer's treatment.
American pharma company Eli Lilly & Co announced on March 31 the start of a phase III clinical trial for a new Alzheimer's treatment.

The new treatment, known as LY450139, will be tested in the IDENTITY (interrupting Alzheimer's Dementia by Evaluating Treatment of Amylold Pathology) trial.

Lilly claims that LY450139 could slow the onset of mild-to-moderate Alzheimer's disease and give patients preserved functionality and quality of life.

During the course of the double-blind, placebo-controlled study, 1,500 patients will take part in the trials in the US and 21 additional countries over the course of 21 months.

Dr Eric Siemers, medical director of Alzheimer's disease research for Lilly, said: "Alzheimer's is a devastating disease that destroys brain cells, affecting everything from a patient's memory to their work and social life. Currently available medications treat the symptoms of Alzheimer's disease but have not been shown to change its underlying progression, creating an urgent unmet medical need."

LY450139 is an investigational gamma secretase inhibitor and has been developed to counteract the degenerative progression of Alzheimer's by excreting an enzyme that creates a sticky protein.

Siemers said that Lilly hopes, "that LY450139 will represent an advance in the attempt to slow the progression of this fatal disease".

31st March 2008


Featured jobs

Subscribe to our email news alerts


Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...